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other Imprinted Transcripts 
Murat Bastepe* 
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Abstract: The currently estimated number of genes in the human genome is much smaller than previously predicted. As 
an explanation for this disparity, most individual genes have multiple transcriptional units that represent a variety of bio-
logically important gene products. GNAS exemplifies a gene of such complexity. One of its products is the -subunit of 
the stimulatory heterotrimeric G protein (Gs), a ubiquitous signaling protein essential for numerous different cellular re-
sponses. Loss-of-function and gain-of-function mutations within Gs-coding GNAS exons are found in various human 
disorders, including Albright’s hereditary osteodystrophy, pseudohypoparathyroidism, fibrous dysplasia of bone, and 
some tumors of different origin. While Gs expression in most tissues is biallelic, paternal Gs expression is silenced in a 
small number of tissues, playing an important role in the development of phenotypes associated with GNAS mutations. 
Additional products derived exclusively from the paternal GNAS allele include XLs, a protein partially identical to Gs, 
and two non-coding RNA molecules, the A/B transcript and the antisense transcript. The maternal GNAS allele leads to 
NESP55, a chromogranin-like neuroendocrine secretory protein. In vivo animal models have demonstrated the importance 
of each of the exclusively imprinted GNAS products in normal mammalian physiology. However, although one or more of 
these products are also disrupted by most naturally occurring GNAS mutations, their roles in disease pathogenesis remain 
unknown. To further our understanding of the significance of this gene in physiology and pathophysiology, it will be im-
portant to elucidate the cellular roles and the mechanisms regulating the expression of each GNAS product. 
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INTRODUCTION 
  The first draft of the human genome DNA sequence was 
reported in 2001 independently by the Human Genome Pro-
ject and Celera Genomics [1, 2]. Since this important land-
mark in medical research, the entire research community has 
had access to a wealth of information that would otherwise 
have taken many years to gather, resulting in a tremendous 
acceleration of virtually all research studies that involve hu-
man biology or disease. With updates of the project, the se-
quence is nearly complete [3, 4]. It is interesting, however, 
that the number of genes in the human genome appears to be 
much smaller than initially estimated. Although the exact 
number of genes in the genome still remains unknown, more 
recent estimate for the number of protein-coding genes is 
between 20,000 and 25,000 [5], which markedly differs from 
the previously predicted number of approximately 100,000 
[6-9]. The currently estimated gene number, of course, ap-
pears quite small, considering the complexity of our species. 
However, the difference between the older and most recent 
predictions of the gene number can be accounted for by the 
presence of multiple transcriptional units associated with 
many individual genes. In fact, the total number of proteins 
encoded by the human genome may be similar to, if not 
higher than, the past estimates of the gene number. This re-
view focuses on the GNAS locus, which exemplifies a com-
plex gene with multiple gene products derived through alter-
native promoter use and alternative pre-mRNA splicing. 
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THE COMPLEX GNAS LOCUS AND Gs 
 The  human  GNAS locus maps to the telomeric end of the 
long arm of chromosome 20 (20q13.2-20q13.3) [10-12], 
while its mouse ortholog is located in distal chromosome 2 
[13, 14]. GNAS in humans and mice appear structurally and 
functionally similar to one and other. This locus has multiple 
promoters and differentially methylated regions (DMR) and 
gives rise to non-coding RNA molecules and transcripts that 
encode functional proteins (Fig. 1). Furthermore, nearly all 
GNAS products show parent-of-origin specific expression. 
Among the multiple products derived from GNAS, the best 
characterized protein is the -subunit of the heterotrimeric 
stimulatory G protein (Gs), which has at least five variants 
that result from alternative pre-mRNA splicing. Derived 
from distinct promoters are at least four different additional 
GNAS products, including the neuroendocrine secretory pro-
tein 55 (NESP55), the extra-large variant of Gs (XLs), the 
A/B transcript, and the GNAS antisense transcript. Most of 
these additional transcripts also undergo alternative splicing 
and, thus, have different variants. 
 Gs is a ubiquitous protein whose activity is essential for 
the cellular actions of many neurotransmitters, autocrine/ 
paracrine factors, and hormones. As in -subunits of other 
heterotrimeric G proteins, activation of Gs by an agonist-
occupied cell surface receptor results in a GDP-GTP ex-
change on Gs, causing dissociation of the latter from G 
subunits and, thereby, allowing both Gs and G to stimu-
late their respective effectors. GTP-bound, free Gs can di-
rectly activate several different effectors, including Src tyro-
sine kinase [15] and certain Ca-channels [16, 17]. However,  
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by far the most ubiquitous and the most extensively investi-
gated effector molecule stimulated by Gs is adenylyl cy-
clase, an integral membrane protein that catalyzes the syn-
thesis of the ubiquitous second messenger cyclic AMP 
(cAMP), thereby triggering an intracellular signaling cascade 
that brings about an agonist- and cell-specific response. The 
activation of adenylyl cyclase and other effectors by Gs is 
tightly regulated. The intrinsic GTP hydrolase (GTPase) 
activity of Gs reverts the GTP-bound Gs to its GDP-bound 
state and, thereby, results in the re-assembly of the G pro- 
tein heterotrimer, which can no longer mediate effector 
stimulation. Mutagenesis experiments often lead to alteration 
in activity and/or subcellular distribution, indicating that 
changes are non-tolerable at many of the amino acid posi-
tions. Particularly, Arg
201 and Gln
227 are critical, since modi-
fications of these residues, such as ADP-ribosylation of 
Arg
201 that can be induced by cholera toxin or mutations at 
either residue, lead to inhibition of the GTPase activity and, 
therefore, render Gs constitutively active [18-21]. The re-
ceptor and GTPase dependent activation cycle of Gs, struc-
tural features of Gs protein, and the roles of specific Gs 
effectors have been reviewed in more detail elsewhere [22, 
23]. 
 Gs is encoded by 13 exons [24], but due to alternative 
pre-mRNA splicing, the Gs transcript has several variants 
(Fig. 2). The long and the short Gs variants (Gs-L and 
Gs-S, respectively) differ from each other by the inclusion 
or exclusion of 45 nucleotides derived from exon 3 [24-26]. 
Nearly all tissues express both of these Gs variants, which 
are typically detected as 52- and 45-kDa protein bands on 
Western blots. In addition, each Gs form either includes or 
excludes a CAG tri-nucleotide (encoding serine) at the start 
of exon 4. Some investigations have revealed small, but po-
tentially important, differences between the activities of Gs-
L and Gs-S. For example, Gs-L has been demonstrated to 
have a greater ability to transmit receptor signaling than 
Gs-S when partially purified proteins from rabbit liver were 
examined [27], although the opposite was suggested in an 
assay system using cultured pancreatic islet cells [28]. 
Moreover, Gs-L appears to release GDP ~2-fold faster than 
Gs-S [29], and consistent with that finding, study of fusion 
proteins involving the 2-adrenergic receptor and either 
Gs-L or Gs-S has shown higher constitutive activity of the 
receptor when it is associated with Gs-L [30]. In addition, 
differences in the subcellular trafficking of these two vari-
ants have been reported in response to activation by agonist, 
forskolin (a direct activator of adenylyl cyclase), or GTPS 
(a stable GTP analog) [31-33]. Currently, it remains unclear 
whether these differences translate into biologically signifi-
cant effects, such as divergence in the variety of effectors 
and/or the efficiency of effector activation. An important 
recent finding regarding the long and short Gs forms is that, 
for the first time, an inactivating mutation in exon 3 has been 
identified in a patient with pseudohypoparathyroidism type-
Ia [34], a disorder known to be caused by inactivating muta-
tions in Gs-coding GNAS exons (see below). The patient 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Multiple imprinted sense and antisense transcripts from the complex GNAS locus. Exons 1-13 encode Gs, which is biallelic in most 
tissues; however, paternal Gs allele is silenced in a small number of tissues, including the renal proximal tubule, thyroid, and pituitary. 
From differentially methylated promoters arise several other transcripts, including the maternally expressed NESP55 and the paternally ex-
pressed XLs. Both of these transcripts use individual first exons that splice onto exons 2-13. In addition, the paternal GNAS allele gives rise 
to a transcript termed A/B (also referred to as 1A or 1’), which also shares exons 2-13 and is presumed to be non-coding. Note that the A/B 
transcript contains an ORF (colored grey) that could lead to a translational product, but the existence of endogenous A/B protein is not sup-
ported experimentally. Another non-coding transcript is also derived from the paternal GNAS allele, but this transcript is made from the an-
tisense strand (AS transcript). Boxes and connecting lines depict exons and introns, respectively. Open rectangles and rectangles filled with 
CH3 show non-methylated and methylated DMRs, respectively. The distance between AS exon 5 and exon NESP55 is ~19 kb and the dis-
tance between exon A/B and exon XL ~35 kb. Maternal (mat) and paternal (pat) GNAS products are illustrated above and below the gene 
structure, respectively, with splicing patterns indicated by broken lines. Filled boxes indicate untranslated sequences. 400    Current Genomics, 2007, Vol. 8, No. 6  Murat Bastepe 
 
with the exon 3 mutation has an apparently mild form of this 
disorder, consistent with the disruption of only one of the 
two main Gs variants, i.e. Gs-L [34]. It is conceivable that, 
depending on the effector selectivity and relative expression 
levels of Gs-L and Gs-S in different tissues, this mutation 
impairs agonist responses in an effector- and tissue-specific 
manner. This possibility remains unexplored.  
  Alternative pre-mRNA splicing leads to another Gs 
variant, termed Gs-N1 (Fig. 2). Identified first in the brain, 
Gs-N1 is truncated in the C-terminus due to splicing of 
exon 3 (or exon 2 in the case of Gs-S) onto a distinct exon 
containing an in-frame termination codon [35]. Exon N1 is 
located between exons 3 and 4. Gs-N1 lacks most func-
tional domains of Gs, and therefore, it is probably unable to 
function in a way similar to the latter. Its cellular role and its 
biological significance remain unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Splice variants of Gs. Alternative splicing of exon 3 leads 
to Gs-L and Gs-S, each of which has subvariants due to alterna-
tive splicing of a serine codon at the start of exon 4. Gs-N1 is 
formed through the use of an exon that comprises an in-frame ter-
mination codon and is located between exons 3 and 4. Boxes and 
connecting lines depict exons and introns, respectively. The alterna-
tively spliced serine codon is depicted as a circle. Splicing patterns 
are indicated by broken lines. Filled boxes indicate 5’ and 3’ un-
translated regions. 
TISSUE-SPECIFIC Gs IMPRINTING 
  Several studies have demonstrated that the expression of 
Gs in most fetal and adult tissues is biallelic, consistent 
with the absence of differential methylation at its promoter 
[36-39]. However, in some human and mouse tissues, Gs 
expression is predominantly maternal, i.e. paternal Gs ex-
pression is silenced. For example, in the renal cortex, mice 
with paternal disruption of Gnas exon 2 exhibit Gs mRNA 
and protein levels that are similar to those seen in wild-type 
littermates, whereas mice with maternal disruption of Gnas 
exon 2 are nearly devoid of Gs mRNA and protein [40], 
indicating that renal cortical Gs expression is derived 
mostly from the maternal allele. This monoallelic, parent-of-
origin specific Gs expression occurs in a tissue-specific 
manner, as both mice with the maternal disruption and mice 
with the paternal disruption show Gs levels in the renal 
medulla that are about 50% of the levels seen in wild-type 
littermates [40]. Similar findings have been reported recently 
in mice heterozygous for either paternal or maternal disrup-
tion of Gnas exon 1, and these studies additionally demon-
strated that Gs expression is also predominantly maternal in 
the thyroid [41]. Consistent with these findings, the active 
maternal Gs promoter shows a greater ratio of tri- to di-
methylated histone-3 Lys
4 compared to the silenced paternal 
promoter in the proximal tubule, whereas the amount of 
methylated histones is similar in maternal and paternal Gs 
promoters in liver, a tissue in which Gs is biallelic [42]. 
  Monoallelic, maternal Gs expression has also been 
documented in human tissues through the analysis of a single 
nucleotide polymorphism located in exon 5. Thus, Gs is 
predominantly maternal in thyroid, pituitary, and ovaries 
[43-45]. On the other hand, biallelic Gs expression has been 
demonstrated in lymphocytes, adrenal, adipocytes, and bone 
cells [44, 46, 47]. The tissue-specific, imprinted expression 
of Gs has important implications in the pathogenesis of 
diseases caused by mutations within GNAS, particularly 
pseudohypoparathyroidism (see below). 
 Several  Gs knockout mouse models have been gener-
ated in order to study the role of Gs in vivo. The mouse 
models with universal Gs disruption will be discussed be-
low in the context of human diseases that are caused by het-
erozygous inactivating mutations within one of the 13 exons 
encoding this protein. In addition, Gs has been condition-
ally ablated, through the use of the Cre-Flox technology, in 
specific tissues including liver, cartilage, bone, and glomeru-
lus, confirming the absolute requirement of Gs in the proper 
function of these tissues [48-51]. 
NOVEL IMPRINTED GENE PRODUCTS OF THE 
GNAS LOCUS 
  Human and mouse studies over the past several years 
have identified novel promoters and exons within GNAS, 
thereby unveiling the previously unrecognized complexity of 
this gene locus. The sense strand comprises at least three 
promoters besides the promoter driving the expression of the 
aforementioned Gs variants (Fig. 2). In addition, there is at 
least one promoter that shows activity on the antisense 
strand. All of the recently described promoters are located 
within CpG islands that show differential, parent-of-origin 
specific methylation. Therefore, the GNAS locus harbors a 
total of four distinct DMRs. Consistent with the differential 
methylation of its promoter, each of the additional GNAS 
product shows an imprinted expression profile in nearly all 
tissues investigated in that regard. 
NESP55 
  The most upstream of the different GNAS promoters with 
respect to the promoter of Gs drives the expression of 
NESP55, a neuroendocrine secretory protein with an appar-
ent molecular mass of 55,000 (Fig. 1). The NESP55 pro-
moter is differentially methylated and active on the non-
methylated maternal allele only [37, 52]. In humans, 
NESP55 protein is encoded by a single exon, while in mice, 
the ORF consists of two separate exons; however, in both 
species, these exons splice onto Gs exons 2-13, which 
comprise the 3’ untranslated region (UTR) [37, 52]. The The GNAS Locus  Current Genomics, 2007, Vol. 8, No. 6    401 
 
predicted molecular mass of NESP55 is 28 kDa, but it has 
the same electrophoretic mobility as a protein of 55 kDa 
[53]. NESP55 is a chromogranin-like protein expressed in 
neuroendocrine tissues, peripheral and central nervous sys-
tem, and some endocrine tissues [53-56]. It is associated 
with the constitutive secretory pathway [57] and can be lo-
cated in cholinergic, peptidergic, and adrenergic neurons 
[58]. In AtT20 cells, a corticotroph-like cell line, NESP55 
has been shown to be exported out into the medium, a proc-
ess which can be blocked markedly by lowering the tempera-
ture and modestly by treatment with a cAMP analog (8-
bromo-cAMP) [59]. In different tissues, differential post-
translational processing of NESP55 leads to smaller pep-
tides, which appear to accumulate during antegrade transport 
of this protein along the axon [58]. One of the putative pep-
tide products, Leu-Ser-Ala-Leu (LSAL), which may be pro-
duced by prohormone convertase cleavage, has been identi-
fied as an endogenous antagonist of the serotonergic 5-HT1B 
receptor subtype [53], although this possibility and its poten-
tial biological significance have yet to be investigated. 
  A knockout of the Nesp55 transcript has been generated 
in mice through introduction, by homologous recombination 
in ES cells, of a small deletion at the translation initiation 
site [60]. This mutation leads to a complete ablation of 
Nesp55 protein after maternal transmission, without affect-
ing the expression of other Gnas transcripts. Nesp55 knock-
out mice appear to have no overt phenotypic abnormalities 
and are fertile. However, behavioral studies of these mice 
using several distinct tasks have revealed increased reactivity 
to novel environments, but these mice do not differ from 
wild-type mice in general locomotion and anxiety. Although 
the role of this protein at the molecular level remains to be 
explored, the findings in the Nesp55 deficient mice appear to 
be consistent with the localization of this protein in specific 
parts of the central nervous system, particularly noradrener-
gic locus coeruleus [61]. In humans, loss of NESP55 expres-
sion occurs as a result of a gain of methylation at its pro-
moter (observed in some patients with pseudohypoparathy-
roidism type-Ib). This defect, however, does not appear to 
lead to an obvious phenotype, because no significant differ-
ences have been identified between patients with the gain of 
NESP55 methylation and those without this epigenetic al-
teration [62, 63]. 
XLs 
  Another promoter, located ~11 kb downstream of the 
NESP55 promoter, drives the expression of XLs mRNA, 
which encodes a protein with partial identity to Gs (Fig. 1). 
As in NESP55, the XLs transcript uses a novel first exon 
(exon XL) that splices onto exons 2-13 of Gs [36, 52]. Un-
like in the case of NESP55, however, the in-frame termina-
tion codon for the XLs transcript is the same as for Gs, 
making the encoded XLs and Gs proteins identical over a 
long C-terminal stretch [64]. Exon XL and the XLs pro-
moter are located in a CpG island methylated on the mater-
nal allele [36, 52]. Consistent with this epigenetic mark, 
XLs is derived exclusively from the paternal allele in all 
investigated tissues [36, 52, 65]; however, variable biallelic 
expression of XLs has been recently demonstrated in clonal 
bone stromal cells [47]. Most abundant expression of XLs 
is detected in neuroendocrine tissues, particularly pituitary, 
but the expression of its mRNA is readily detected by North-
ern blot or RT-PCR in various tissues, including brain, pan-
creas, heart, kidney, and adipose tissue [36, 64, 66, 67]. As 
demonstrated in the rat nervous system, XLs expression is 
developmentally regulated [68]. 
 Because  XLs shares significant amino acid identity with 
Gs, it comprises most domains of the latter shown to be 
functionally important. Furthermore, the C-terminal end of 
the XL domain has significant homology to the exon 1 en-
coded portion of Gs. Consistent with the high degree of 
overall similarity between XLs and Gs, various studies 
have demonstrated that XLs is able to act in a manner simi-
lar to Gs in vitro. First, XLs show enhanced ADP ribosy-
lation and an increased sucrose-density sedimentation rate 
upon addition of the G subunits, indicating that XLs is 
able to form a heterotrimer [69]. Second, expression of an 
XLs mutant carrying the homolog of the Gs Gln
227 muta-
tion results in elevated cAMP formation, indicating that 
XLs can stimulate adenylyl cyclase at least in the basal 
state [69]. Third, XLs can mediate receptor-stimulated 
cAMP formation when overexpressed in opossum kidney 
cells that show endogenous Gs expression [70] and in 
mouse embryonic fibroblasts that endogenously lack Gs 
and XLs due to homozygous disruption of Gnas exon 2 
[71]. Finally, mutations that impair Gs activity have similar 
effects on XLs activity when introduced into the backbone 
of the latter [70]. Interestingly, however, beta-adrenergic 
stimulation seemingly fails to elicit cAMP generation in 
XLs transfected S49 lymphoma cells that are also Gs defi-
cient (cyc
- clone) [69]. Furthermore, attempts to show cou-
pling of XLs to receptors have failed, using PC12 cells 
transfected with XLs cDNA and pituitary membranes [69]. 
Taken together, these findings suggest that the Gs-like ac-
tivity of XLs may be cell specific. 
  As illustrated in Fig. (3A), XLs has several different 
variants. Similar to Gs, it uses exon 3 alternatively, thus 
having at least a long and a short variant. In addition, analo-
gous to Gs-N1, a C-terminally truncated XLs variant, 
termed XLs-N1, also exists. Human XLs-N1 appears to 
have a subvariant produced by inclusion of sequences from 
two additional exons, A20 and A21, located immediately 
following exon XL [36]. A similar subvariant has also been 
demonstrated for rat XLs-N1 [66]. The introduction of 
these additional sequences into XLs-N1 results in a frame-
shift, leading to a putative protein with partial identity to 
XLs but not to Gs. Functional significance of XLs-N1 
and its variants remains unknown. 
  There is evidence for the existence of a long XLs tran-
script, termed XXLs, which extends in the 5’ direction (Fig. 
3A). The XXLs transcript is supported by Est databases and 
a single study that could amplify portions of the XXLs tran-
script by RT-PCR [72]. A long XLs transcript has also been 
revealed by Northern blot in mouse heart and adipose tissue 
[67]. In fact, based on existing data, the translation initiation 
codon for XLs does not match with that corresponding to 
the longest open reading frame (ORF), making it likely that 
an N-terminally extended XLs variant is expressed at least 
in some tissues. Est databases also suggest the existence of 
transcripts that correspond to XXLs-N1, but neither the role 
of XXLs nor the role of XXLs-N1 is currently known. 
Interestingly, however, unlike the XL domain in XLs and 402    Current Genomics, 2007, Vol. 8, No. 6  Murat Bastepe 
 
main in XLs and XLs-N1-- the portion encoded by exon 
XL -- the N-terminally extended part in XXLs and XXLs-
N1 is highly conserved among mammals, suggesting that it 
may represent a functionally significant domain. 
 The  XLs mRNA has a second ORF that encodes an-
other protein termed ALEX (for alternative protein encoded 
by XLs mRNA), which uses a termination codon located 
within exon XL and is, therefore, smaller than XLs (Fig. 
3B). In vitro studies have shown that ALEX, which has a 
predicted molecular mass of 38 kDa, can interact with XLs 
[73, 74]. An insertion polymorphism within XLs mRNA, 
affecting both proteins, appears to impair this interaction, a 
finding that has been offered as an explanation as to why 
some individuals carrying this insertion polymorphism show 
elevated agonist-induced cAMP accumulation in platelets 
[74]. However, this increased agonist responsiveness could 
also result from elevated Gs levels, which was demon-
strated in several individuals who carried the same insertion 
polymorphism and had increased bleeding tendency [75]. 
Hence, the significance of XLs-ALEX interaction on XLs 
or Gs function remains to be clarified. Of note, this alterna-
tive ORF also extends in to the XXLs mRNA, generating a 
putative N-terminally extended ALEX variant, termed 
ALEXX [72]; however, there are currently no available ex-
perimental data to suggest that this protein actually exists. 
  Exon XL has been disrupted in mice through introduction 
of a small deletion into the beginning part of both XLs and 
ALEX ORF; this disruption appears to preserve the im-
printed expression of other Gnas transcripts [67]. The mice 
with paternal inheritance of the disrupted XLs allele 
(Gnasxl knockout mice) lack XLs expression, consistent 
with the exclusive paternal expression of the XLs tran-
script. The Gnasxl knockout pups show defective suckling, 
hypoglycemia, growth retardation, and early postnatal mor-
tality. Despite having hypoglycemia, the Gnasxl knockout 
mice show reduced glucagon levels and inappropriately 
normal serum catecholamine and cortisol levels, suggesting a 
possible impairment of the physiological responses to hypo-
glycemia. When crossed into the CD1 background, about 
20% of the Gnasxl knockout animals survive with an appar-
ently normal life-span. However, these mice display in-
creased glucose tolerance and insulin sensitivity, as well as a 
hypermetabolic state associated with reduced adiposity and 
hypolipidemia [67]. In addition, circulating levels of norepi-
nephrine is elevated in these animals, indicating increased 
sympathetic nervous system activity, which explains, at least 
in part, the defects in the energy metabolism [76]. On the 
other hand, adipocyte-autonomous factors appear less likely 
to be involved in these phenotypes, because XLs is not ex-
pressed in the adipocytes of adult wild-type mice [76]. 
  The genetic alteration in the Gnasxl knockout mice is 
predicted to disrupt not only XLs but also XLs-N1, 
ALEX, XXLs, XXLs-N1 and ALEXX. It thus appears 
unlikely that the phenotype of Gnasxl knockout mice is due 
solely to XLs deficiency. Nonetheless, a similar phenotype 
is present in mice with paternal Gnas exon 2 disruption [77-
79] and in mice with a paternally inherited missense muta-
tion in exon 6 [80, 81], thereby ruling out the involvement of 
ALEX, XLs-N1, and XXLs-N1 deficiency in the pheno-
types of the Gnasxl knockout mice. Thus, it is more likely 
that the deficiency of XLs and/or XXLs underlies the find-
ings observed in the latter mouse model, although this con-
clusion needs to be verified through further investigation. It 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). XLs and its multiple variants. XLs is derived from a promoter upstream of that which drives the expression of Gs. Panel A. Al-
ternative splicing leads to different XLs variants that are analogues to Gs variants. In addition, an N-terminally extended XLs variant, 
termed XXLs, is made, representing the 5’ extension of the ORF. For simplicity, GNAS exons located upstream of exon XL are not shown. 
Panel B. XLs and XXLs mRNA include two ORFs each. The second ORF leads to ALEX or ALEXX, respectively. The GNAS Locus  Current Genomics, 2007, Vol. 8, No. 6    403 
 
is important to note that the phenotype of the Gnasxl knock-
out mice differs, by and large, from the phenotype of mice 
heterozygous for disruption of Gnas exon 1, in which Gs, 
but not XLs, is ablated [41, 82]. In fact, Gnasxl knockout 
mice demonstrate slightly elevated basal and isoproterenol 
stimulated cAMP levels in brown adipose tissue at birth [67]. 
These findings suggest that XLs has a role distinct from the 
role of Gs in mammals, and that it may oppose, at least in 
certain tissues, the actions of Gs. 
  Findings that are reminiscent of those observed in Gnasxl 
knockout mice and the mice with paternal Gnas exon 2 dis-
ruption have been reported in two unrelated children with 
large paternal deletions of chromosome 20q13.3 that com-
prise the GNAS locus [83]. These findings included perinatal 
growth retardation, intractable feeding difficulties, and loss 
of subcutaneous adiposity, as well as dysmorphic facial fea-
tures. Because the deletion involved, in each case, the entire 
GNAS locus, it is possible that the phenotype reflects, at least 
partially, the deficiency of Gs and/or the other paternally 
expressed GNAS products (see below). 
The A/B Transcript 
  About 2.5 kb upstream of the Gs promoter lies another 
promoter that drives the nearly ubiquitous expression of an-
other transcript termed A/B (also termed 1A and 1’) [84-86]. 
The A/B promoter, despite being in close proximity to the 
Gs promoter, reside within a DMR, where the maternal 
allele is methylated and repressed, while the paternal allele is 
non-methylated and active (Fig. 2). The first exon of the A/B 
transcript, as in NESP55 and XLs, splices onto Gs exons 
2-13. However, exon A/B does not contain an in-frame 
translation initiation codon, and as supported by evidence 
from in vitro translation assays [86], translation can be initi-
ated by an in-frame AUG located in exon 2, leading, pre-
sumably, to a variant of Gs that has a truncated N-terminus. 
Transfection of COS cells with A/B cDNA results in the 
expression of a protein that localizes to the plasma mem-
brane [86]. Based on these features, it is conceivable that the 
A/B protein interacts with adenylyl cyclase and may, there-
fore, exert a dominant negative effect on Gs actions. This 
possibility remains to be investigated. 
  On the other hand, it appears more likely that the A/B 
transcript is non-coding, as the existence of an endogenous 
A/B protein is not supported by experimental evidence. Fur-
thermore, similar to other non-coding RNA molecules in the 
genome, the A/B transcript and/or the exon A/B DMR has an 
important role in regulating gene expression from GNAS. 
Unlike the DMRs comprising the promoters of NESP55 and 
XLs, the exon A/B DMR has been shown to be a germ-line 
imprint mark [85]. It has also been shown that this DMR is 
associated with allele-specific differences in histone modifi-
cations consistent with an active paternal (histone acetylation 
and histone-3 Lys
4 methylation) and an inactive maternal 
(histone-3 Lys
9 metyhlation) promoter [42, 87]. In addition, 
paternal ablation of the A/B DMR results in derepression of 
the Gs transcript in those tissues where paternal Gs ex-
pression is normally silenced, such as the renal cortex [81, 
88]. Thus, it appears that the non-methylated A/B DMR 
and/or active A/B transcription is necessary for the tissue-
specific paternal silencing of Gs. Consistent with this find-
ing, maternal exon A/B is unmethylated and the maternal 
A/B promoter is derepressed in patients with pseudohypop-
arathyroidism type-Ib [63, 89, 90], who are thought to have a 
lack of Gs expression in the proximal tubule due to silenc-
ing of the maternal Gs promoter (in addition to the silenc-
ing of the paternal Gs promoter that occurs normally in the 
same tissue; see below for further discussion). 
  The mechanisms underlying the role of A/B in the tissue-
specific silencing of paternal Gs expression are not well 
understood. Considering that the A/B transcription takes 
place more broadly than does paternal Gs silencing, a 
mechanism that involves simple competition between the 
promoters of these two transcripts is unlikely. On the other 
hand, a plausible hypothesis involves a mechanism whereby 
the paternal A/B DMR binds either a repressor that directly 
silences the Gs promoter or an insulator that prevents the 
effects of an upstream enhancer on the Gs promoter. A 
mechanism similar to the latter has been demonstrated for 
the Igf2-H19 locus, in which methylation-sensitive binding 
of CTCF hinders Igf2 enhancer activity [91, 92]. To address 
these possibilities, it may be necessary to generate and study 
additional mouse models in which A/B transcript is disrupted 
without the deletion of its promoter region. 
The GNAS Antisense Transcript 
  A promoter located immediately upstream of the XLs 
promoter drives expression of an antisense transcript, which 
extends past the exon(s) encoding NESP55 [93, 94] (Fig. 2). 
In mice, the mature antisense transcript (termed Nespas or 
Gnasas) encompasses both Nesp55 exons 1 and 2 and the 
intervening intron [94], while in humans, it has no overlap 
with exon NESP55 [93]. There are at least five distinct exons 
that form the human GNAS antisense transcript, but alterna-
tive splicing results in at least six variants. The largest open 
reading frame is predicted to encode a polypeptide of 97 
amino acids that share no homology to known proteins [93]. 
Taken together these features suggest that the antisense tran-
script is non-coding. Indeed, similar to the promoter of A/B, 
the promoter of the GNAS antisense promoter resides in a 
DMR and is active exclusively on the paternal allele [65, 93, 
94]; however, the antisense transcript shows biallelic expres-
sion in the adrenal and testes [65]. Consistent with allele-
specific expression, the paternal antisense promoter is asso-
ciated with acetylated histone and histone-3 Lys
4 methyla-
tion, while the maternal promoter lacks histone acetylation 
and carries histone-3 Lys
9 methylation [87]. Furthermore, 
studies in mice have shown that the maternal methylation at 
the antisense promoter is present even in the oocytes and, 
therefore, represents a germ-line imprint mark [95]. 
  Paternal deletion of the antisense promoter in mice re-
sults in derepression of Nesp55 in cis, thereby leading to 
biallelic expression of the latter [96]. This finding indicates 
that at least one of the roles of the antisense transcript is to 
silence the paternal Nesp55 promoter. However, the effect of 
the deletion of the antisense promoter is not limited to 
Nesp55 expression. First, the deleted region evidently com-
prises an enhancer of the XLs promoter, resulting in a dra-
matic reduction in XLs expression and, thus, a phenotype 
similar to that observed in Gnasxl knockout mice. Second, 
mice with the paternal deletion exhibit a modest decrease in 
A/B expression combined with an increase in the methyla-
tion of the A/B promoter. Third, in those tissues where Gs 404    Current Genomics, 2007, Vol. 8, No. 6  Murat Bastepe 
 
is normally silenced from the paternal allele, the diminished 
A/B expression is associated with an increase in Gs expres-
sion in cis, i.e. the tissue specific Gs imprinting is relaxed. 
These findings clearly demonstrate the importance of the 
antisense transcript in the regulation of imprinted gene ex-
pression from the GNAS locus. Nonetheless, what causes the 
reduction of paternal A/B expression remains unclear. Is it 
the derepression of Nesp55, the reduction of XLs expres-
sion, or the deletion of the genomic region containing the 
antisense promoter? 
HUMAN DISEASES ASSOCIATED WITH GNAS MU-
TATIONS 
  Consistent with the pivotal role of Gs in multiple bio-
logical responses, mutations that affect the activity or ex-
pression of Gs lead to human disease. However, there are 
no disorders caused by inactivation of both Gs alleles, i.e. 
homozygous inactivating Gs mutations, and this is consis-
tent with the early embryonic lethality observed in mice with 
homozygous disruption of either Gnas exon 2 or Gnas exon 1 
[40, 41, 82]. Thus, complete loss of Gs activity is not com-
patible with life. Moreover, there are mutations that cause 
constitutive Gs activity, but these are virtually never inher-
ited and are of somatic origin, indicating that universal Gs 
overactivity is embryonic lethal, as well. 
Endocrine Adenomas and other Tumors 
  Many hormones bind Gs-coupled receptors in order to 
activate their endocrine glands for proliferation, differentia-
tion, and hormone secretion. Accordingly, mutations that 
cause constitutive Gs activity are found in various function-
ally active endocrine adenomas, including those that origi-
nate from pituitary somatotrophs. In about 40% of patients 
with growth hormone secreting pituitary adenomas, constitu-
tively activating Gs missense mutations at either Arg
201 or 
Gln
227 have been identified in DNA from the tumor tissue, 
but not in DNA from peripheral blood [20, 97]. Since these 
mutant Gs forms are identified in tumors and are present in 
one of the Gs alleles only, they are referred to as the gsp 
oncogene [20, 97]. Other endocrine tumors also bare the gsp 
oncogene, including corticotroph, thyroid, parathyroid, and 
adrenocortical tumors, but their frequency in the patient 
population appears to be low based on many studies (re-
viewed in [98]). Some studies have recently identified the 
gsp oncogene in ovarian granulosa cell tumors and testicular 
stromal Leydig cell tumors as a possible cause of tumori-
genesis and as a possible prognostic marker [99, 100]. In a 
more recent study, 5 of 30 patients with clear cell renal car-
cinoma have been shown to carry constitutively activating 
Gs mutations in the tumor tissue [101]. Hence, the gsp on-
cogene can be present in a wide variety of tumors that 
mostly, but not exclusively, involve classic endocrine tis-
sues. Data from transgenic mouse models and cell culture 
assays have shown that constitutive Gs activity can lead to 
hyperplasia and increased hormone secretion in endocrine 
cells [102, 103]. However, although a recent study impli-
cates sustained activation of extracellular signal-regulated 
kinase in increased hormone secretion [104], the signaling 
pathways downstream of the gsp oncogene currently remain 
incompletely understood. 
McCune-Albright Syndrome 
  This syndrome, independently described by McCune 
[105] and Albright et al. [106], is characterized by a triad of 
sexual precocity, fibrous dysplasia of bone, and hyperpig-
mented skin lesions termed café-au-lait spots. Patients with 
the McCune-Albright syndrome (MAS) are mosaic for con-
stitutively activating Gs mutations that occur during early 
embryonic development [107-109]. This is consistent with 
the observation that MAS occurs sporadically and is never 
transmitted to the next generation. All identified mutations 
are at residue Arg
201 (Cys or His), suggesting that changes in 
residue Gln
227 may result in higher constitutive activity and 
are, therefore, less viable. Because of the mosaicism, patients 
with MAS show significant variation in their clinical presen-
tation. In general, the abnormalities involve bone, skin, and 
endocrine organs. Fibrous dysplastic bone lesions are usually 
found in multiple bones. It is important to note that some 
patients with the constitutively activating Gs mutations 
present with fibrous dysplasia alone, affecting either a single 
bone or multiple bones. In patients with isolated fibrous dys-
plasia, histological changes appear to be indistinguishable 
form those seen in the context of MAS [110, 111]. As in 
patients with MAS, nearly all isolated cases of fibrous dys-
plasia are associated with GNAS mutations at Arg
201; how-
ever, a study using a mutation-specific restriction enzyme 
digest assay has recently identified three Gln
227 (to Leu) mu-
tations among a total of 56 samples [112]. The skin lesions, 
which typically have irregular borders, can be single or mul-
tiple light brown hyperpigmented areas arranged in segmen-
tal patterns that follow the developmental lines of Blaschko 
[106, 109]. Endocrine abnormalities, in addition to preco-
cious puberty, can be summarized as hyperplasia and in-
creased function of many different glands, including thyroid, 
adrenal, and pituitary [113-115]. Some patients with MAS 
also exhibit urinary phosphate wasting, hypophosphatemia, 
and bone mineralization defects observed as rickets or os-
teomalacia [113, 114]. While the latter findings are consis-
tent with the role of Gs in mediating the phosphaturic ac-
tions of parathyroid hormone in the renal proximal tubule, 
recent data shows that serum phosphate in MAS patients is 
negatively correlated with the level of fibroblast growth fac-
tor-23 [116-118], suggesting that the elevation of this phos-
phaturic factor is responsible, at least partly, for the hypo-
phosphatemia observed in these patients. In addition to the 
various endocrine defects discussed above, there are rare 
reports of non-endocrine abnormalities associated with 
MAS, including liver and cardiac abnormalities, and neuro-
logical defects. The endocrine and non-endocrine findings in 
MAS have been reviewed elsewhere in greater detail [98]. 
Pseudohypoparathyroidism Type-Ia, Pseudopseudohypo- 
parathyroidism, and Progressive Osseous Heteroplasia 
  Fist described by Albright and colleagues [119], Pseudo- 
hypoparathyroidism (PHP) refers to end-organ resistance to 
multiple hormones that primarily involves the actions of 
parathyroid hormone. PTH exerts its actions in bone and 
kidney through the PTH/parathyroid hormone-related pep-
tide receptor (PTHR1), which couples to Gs and, less effec-
tively, to Gq [120, 121]. PTH increases bone turnover, lead-
ing to mobilization of calcium and phosphate from bone 
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thesis of 1,25-dihydroxyvitamin D and inhibits phosphate 
reabsorption from the glomerular filtrate, while in the distal 
renal tubule, it enhances the absorption of calcium mediated 
via transcellular mechanisms. Exogenous administration of 
biologically active PTH, used previously as a diagnostic test 
[124], results in a blunted excretion of urinary phosphate in 
both PHP type-I and PHP type-II, but this defect is accom-
panied by blunted nephrogenous cAMP production in PHP 
type-I only; the PTH-induced generation of nephrogenous 
cAMP is normal in PHP type-II [119, 125]. Clinically, PHP-I 
is far more frequent than PHP-II, for which underlying mo-
lecular defects are not well understood. On the other hand, 
significant advances have been recently made regarding the 
molecular pathology underlying PHP-I. 
  Some patients with PHP-I display distinctive physical 
features collectively termed Albright’s hereditary osteodys-
trophy [119]. These features include obesity, short stature, 
ectopic ossification, brachydactyly, and mild mental retarda-
tion, although there is significant patient-to-patient variation 
in the range and severity of these features. The presence of 
both PTH-resistance and AHO defines patients with PHP 
type-Ia. Gs mRNA and protein levels are reduced to half in 
easily accessible tissues from these patients [126-128]. This 
defect results from heterozygous inactivating mutations 
within one of the thirteen Gs coding GNAS exons [129, 
130]. Scattered throughout the gene, various different types 
of mutations, such as insertions, deletions, and missense and 
nonsense changes, have been identified, which is consistent 
with their inactivating nature. An extensive list of the muta-
tions associated with this disorder can be found under 
OMIM entry #139320 at http://www.ncbi.nlm.nih.gov. 
 Because  Gs is not exclusive for PTH signaling, PHP-Ia 
patients also show resistance to some other hormones whose 
actions depend on Gs signaling, including thyroid stimulat-
ing hormone (TSH), gonadotropins, and growth hormone 
releasing hormone (GHRH) [131-135]. It is worth noting 
that not all hormone actions that rely on Gs are impaired in 
PHP-Ia. For example, there is no resistance to vasopressin 
[136, 137] or to hormones in the hypothalomo-pituitary-
adrenal axis [134, 136, 138]. 
 Inactivating  Gs mutations found in PHP-Ia patients are 
also present in patients who lack hormone resistance but 
present with AHO features, a condition referred to as pseu-
dopseudohypoparathyroidism (PPHP) [139]. Mutations in 
patients with PPHP are often identical to those in PHP-Ia 
patients. In fact, both disorders typically co-exist in the same 
kindred [129, 140], with the gender of the affected parent 
determining whether the offspring will have PHP-Ia or 
PPHP: maternal inheritance leads to PHP-Ia, whereas pater-
nal inheritance leads to PPHP [141, 142]. Thus, hormone 
resistance (PHP-Ia) is inherited only from female obligate 
carriers, a mode of inheritance that is consistent with the 
predominantly maternal expression of Gs in certain tissues. 
It is important to note that the repertoire of hormone resis-
tance in PHP-Ia correlates well with the tissues in which 
maternal, monoallelic Gs expression takes place, underscor-
ing the significance of Gs imprinting in the pathogenesis of 
PHP-Ia. 
  AHO features are present in both PHP-Ia and PPHP pa-
tients, and therefore, the molecular mechanisms underlying 
AHO presumably entail Gs haploinsufficiency rather than 
imprinting. Gs haploinsufficiency has been demonstrated in 
the growth plate of mice chimeric for wild-type cells and 
cells heterozygous for disruption of either the maternal or the 
paternal Gnas exon 2 [143]. In the chimeric setting, the mu-
tant chondrocytes undergo hypertrophic differentiation 
sooner than wild-type chondrocytes, and because this finding 
is qualitatively similar to (albeit far less severe than) that 
observed in chondrocytes with homozygous Gs ablation 
under the same conditions, it indicates Gs haploinsuffi-
ciency. While this study strongly suggests that the short stat-
ure and the brachydactyly seen in patients with AHO reflect, 
at least in part, Gs haploinsufficiency in the growth plate, 
some features of AHO may still involve Gs imprinting in 
the pathogenesis. For example, a recent study has clearly 
shown that obesity is more prominent in PHP-Ia patients 
than PPHP patients [144]. Thus, it appears that Gs may be 
imprinted in more tissues than currently recognized, such as 
in parts of the brain that controls satiety and body weight. It 
is also possible that disruption of other imprinted GNAS gene 
products contribute to the pathogenesis of AHO. Supporting 
this hypothesis, chondrocytes with paternal Gnas exon 2 
disruption exhibit a slightly, but significantly, higher degree 
of Gs haploinsufficiency than chondrocytes with maternal 
Gnas exon 2 disruption [143]. More detailed characterization 
of the different AHO features between patients with pater-
nally and maternally inherited Gs mutations are likely to 
provide further insights into the understanding of the mecha-
nisms underlying AHO. 
  Progressive osseous heteroplasia (POH) describes a se-
vere, debilitating disease characterized by ectopic intramem-
branous bone formation that affects not only the subcutis, but 
also the skeletal muscle and the deep connective tissue [145]. 
Heterozygous inactivation mutations within the Gs coding 
GNAS exons have also been identified in patients with POH. 
In fact, some of those mutations are identical to those found 
in patients with PHP-Ia or PPHP [145-147]. It is therefore 
possible that POH is an extreme manifestation of the ectopic 
bone formation of AHO that normally involves the subcuta-
neous tissue. However, POH is rarely accompanied with any 
AHO features or hormone resistance [146, 148]. Further-
more, in many kindreds, it has been shown that the disease 
develops only after paternal inheritance [147], suggesting 
that genomic imprinting also plays a role in the pathogenesis 
of POH. Because this disorder is paternally inherited, defi-
ciency of GNAS products that show paternal specific expres-
sion and share exons with Gs, such as XLs, could contrib-
ute to ectopic bone formation. Consistent with this hypothe-
sis, no mutations in exon 1 has thus far been reported in 
cases with isolated POH [147, 149, 150]. However, the roles 
of XLs and other imprinted GNAS products in POH remain 
currently undefined. 
PHP Type-Ib 
  Some patients with PTH-resistance lack AHO and any 
additional hormone resistance, defining the typical features 
of PHP type-Ib (PHP-Ib). Recent studies have demonstrated 
that some PHP-Ib patients also have mild TSH resistance in 
addition to PTH resistance [89, 90, 151]. Furthermore, a sin-
gle study described several patients who showed both the 
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mild features of AHO [152], suggesting more variation in the 
phenotype. Unlike in PHP-Ia, Gs activity is typically nor-
mal in easily accessible cells from these patients, thus ex-
cluding mutations within Gs coding GNAS exons [131, 
153]. Nonetheless, in three related patients with an apparent 
diagnosis of PHP-Ib an in-frame, tri-nucleotide deletion has 
been identified within exon 13 [154]. Expressed in HEK293 
cells, an embryonic kidney derived cell line, this Gs mutant 
was shown to affect the signaling of PTH, but not of TSH, 
LH, or isoproterenol, thus explaining the isolated PTH resis-
tance. The selective effect of this mutation on PTH signal-
ing, however, could not be verified in a subsequent study 
[70], and it is possible that the discrepancy between the two 
studies stems from the use of different cell types and/or as-
says; the second study used mouse embryonic fibroblasts 
null for endogenous Gs [70, 71]. Alternatively, the three 
patients may have PHP-Ia, consistent with the observation 
that two of them exhibited advanced bone age [154], which 
is a typical sign of AHO. Since the urinary cAMP response 
to exogenously administered PTH is blunted in PHP-Ib pa-
tients [131], defects in the gene encoding PTHR1 seemed 
like a good candidate at the time. However, several studies 
have ruled out this possibility [153, 155-157]. 
  PHP-Ib is often sporadic, but a number of familial cases 
have also been described. A careful analysis of these pedi-
grees has revealed that the PTH resistance in PHP-Ib devel-
ops only if the genetic defect is inherited from a female car-
rier [158], i.e. the mode of inheritance is identical to that 
observed for hormone resistance in PHP-Ia. Genetic linkage 
studies using some of these kindreds have mapped the ge-
netic defect to a region of chromosome 20q that comprises 
the GNAS locus [158, 159]. Moreover, most PHP-Ib patients 
exhibit  GNAS imprinting defects [63, 89]. Although these 
defects involve multiple GNAS D M R s  i n  s o m e  c a s e s ,  t h e  
most consistent defect is a loss of imprinting at the A/B 
DMR, i.e. loss of methylation at the A/B promoter and exon 
combined with biallelic A/B expression, which appears to be 
an isolated defect in most familial PHP-Ib cases [89, 160]. 
Based on these findings, the genetic mutation responsible for 
PHP-Ib is thought to disrupt an imprinting regulatory ele-
ment of GNAS. The most frequent mutation, identified thus 
far in more than 30 unrelated kindreds, is a unique 3-kb mi-
crodeletion located about 220 kb upstream of exon A/B 
[160-163] (Fig. 4). Flanked by two 391-bp repeats, the 3-kb 
microdeletion removes exons 4-6 of STX16, the gene encod-
ing syntaxin-16. The second mutation is a 4.4-kb microdele-
tion that overlaps with the former and removes STX16 exons 
2-4; this mutation, unlike the 3-kb microdeletion, has been 
found in only one kindred thus far [164]. These mutations 
cause disease only after maternal inheritance, and each af-
fected individual carrying either of these mutations displays 
an isolated loss of exon A/B imprinting, thereby indicating 
that the mutations disrupt a cis-acting element that controls 
imprinting at the exon A/B DMR [160, 164]. This element 
may lie within the 1.3-kb region where the two deletions 
overlap. The overlapping region comprises exon 4, which is 
evolutionarily conserved and lies within a small CpG-rich 
region that lacks differential methylation [160]. It is also 
possible that the identified deletions independently disrupt a 
large control element that spans STX16. On the other hand, 
disruption of STX16 is not considered to be involved in the 
pathogenesis of PHP-Ib, because there is no evidence that 
this gene is imprinted [160, 164]. 
  All sporadic and some familial PHP-Ib cases show epi-
genetic defects at one or more GNAS DMRs in addition to 
the exon A/B DMR [63, 89]. These defects often consist of a 
loss of imprinting at exon A/B, exon XL, and the promoter 
of the antisense transcript and a gain of imprinting at exon 
NESP55. Two unrelated familial cases with such GNAS im-
printing abnormalities have been shown to carry maternally 
inherited deletions of the entire NESP55 DMR including 
exons 3 and 4 of the antisense transcript [165], revealing the 
putative location of another control element required for the 
imprinting of the entire maternal GNAS allele (Fig. 4). The 
presence of similarly large deletions at the NESP55 DMR 
has been excluded in a number of sporadic PHP-Ib cases 
[165]. 
 The  broad  GNAS epigenetic defects seen in the sporadic 
cases are often such that the maternal allele has attained a 
paternal epigenotype. Accordingly, a sporadic PHP-Ib case 
has been shown to have paternal uniparental isodisomy of 
the entire chromosome 20q (patUPD20q) [90]. Leading to 
the diagnosis were PTH-resistance and mild TSH resistance 
in the absence of typical AHO findings, although the patient 
had additional abnormalities, including developmental delay 
and craniosynostosis, which may have resulted from either 
disrupted expression of other imprinted genes or from un-
masking of recessive defects present on paternal chromo-
some 20q. Hence, patUPD20q is a cause of sporadic PHP-Ib, 
and it is possible that interstitial paternal UPDs in this region 
could lead to PHP-Ib as a more common cause of this disor-
der in the sporadic cases. It has also been suggested that 
some cases of sporadic PHP-Ib is caused by stochastic de-
fects in the imprinting process [162]. In either case, the off-
spring of affected females would be predicted to have nor-
mal  GNAS imprinting and normal proximal tubular PTH 
responsiveness even if they inherit the disease-associate al-
lele. 
  Sporadic PHP-Ib cases typically differ from familial 
PHP-Ib cases in the nature of the GNAS epigenetic defects 
they exhibit, yet evaluation of many cases with these PHP 
forms indicates that the divergence in the epigenetic features 
do not directly translate into differences in clinical presenta-
tion. The age of onset and the severity of hypocalcemia and 
hyperphosphatemia that result from PTH resistance appear to 
be similar in sporadic and familial cases [62]. As explained 
above, Gs expression is also predominantly maternal in the 
pituitary somatotrophs [43]; however, growth hormone defi-
ciency and short stature are not typical clinical features of 
PHP-Ib. It is possible that the epigenetic defects do not affect 
Gs expression in this tissue, thereby allowing unimpaired 
GHRH signaling. This could suggest that the mechanisms 
underlying Gs imprinting are different between the pituitary 
and the proximal tubule. Alternatively, GHRH resistance 
may be present in patients with PHP-Ib, but it may be too 
mild to become clinically manifest. This is similar to the 
TSH resistance in PHP-Ib, which can be absent in many 
PHP-Ib patients, is milder than in PHP-Ia, and can be ac-
counted for by the partial imprinting of Gs in the thyroid 
[151]. Mild short-stature has been recently reported in some 
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defects [152], consistent with GHRH resistance and resultant 
growth hormone deficiency. Nevertheless, it remains un-
known whether patients with PHP-Ib have reduced Gs ex-
pression in the pituitary and whether they display GHRH 
resistance. 
  The common defect in nearly all PHP-Ib cases is the loss 
of GNAS exon A/B imprinting. In fact, this epigenetic defect 
is necessary for the development of PTH resistance, as 
documented in a PHP-Ib kindred in whom some individuals 
lacked both loss of A/B imprinting and PTH resistance de-
spite maternally inheriting the disease-associated haplotype 
on 20q [166]. The loss of A/B imprinting on the maternal 
allele is predicted to silence, in cis, Gs transcription in the 
proximal tubule. Therefore, methylation of exon A/B DMR 
and/or the repression of A/B transcription appear to be re-
quired for maternal Gs expression in this and, probably, 
other tissues, such as the thyroid gland. Supporting this no-
tion, ablation of the paternal exon A/B region derepresses 
Gs in cis in tissues where this signaling protein is paternally 
silenced [81, 88] and, furthermore, rescues the PTH resis-
tance phenotype observed in mice with a point mutation in 
maternal Gnas exon 6 [80, 81]. 
ANIMAL MODELS OF THE GNAS-RELATED DIS-
EASES 
PHP-Ia/PPHP 
  Before the evidence that several different GNAS tran-
scripts, in addition to Gs, utilize exon 2, a mouse model of 
PHP-Ia was generated by targeted disruption of this exon 
[40]. Homozygous disruption of exon 2 results in early em-
bryonic lethality. Furthermore, paternal heterozygous disrup-
tion leads to lethality within the first 24 h after birth, and 
maternal heterozygous disruption results in death within the 
first three weeks. Surviving animals are fertile and appear to 
have normal life spans. As explained above, mice with pa-
ternal disruption of Gnas exon 2 have severe defects that are 
similar to those seen in mice with paternal disruption of 
Gnasxl [67], including reduced adiposity, which is not seen 
in patients with paternally inherited inactivating Gs muta-
tions (PPHP); these patients are typically overweight. On the 
other hand, both the maternal and the paternal Gnas exon 2 
knockout mice appear smaller than their littermates, reminis-
cent of the short stature observed in patients with AHO. Fur-
thermore, the exon 2 knockout mice prove to be a good 
model of PTH resistance. Reflecting the tissue-specific si-
lencing of paternal Gs in the proximal tubule, PTH-
resistance, characterized by hypocalcemia, hyperphos-
phatemia, and elevated serum PTH, is present only after ma-
ternal inheritance of the disrupted allele [40]. In addition, 
PTH stimulation of proximal tubule extracts from mice with 
the maternal disruption, but not with the paternal disruption, 
fail to increase cAMP levels. Similar to the observations in 
PHP-Ia patients, the urine concentrating ability of the kidney 
in response to vasopressin is unimpaired in both the maternal 
and the paternal knockouts. Hence, although the findings 
resulted from the disruption of exon 2 are rather complicated 
due to the use of this exon by not only Gs but also several 
other GNAS products (particularly XLs), this animal model 
is able to phenocopy PHP-Ia to a significant extent. 
 Chen  et al. [82] and Germain-Lee et al. [41] have inde-
pendently generated another model of PHP-Ia through tar-
 
 
 
 
 
 
 
 
 
 
Fig. (4). Regulation of gene expression from the GNAS locus. The maternal GNAS allele comprises two germ-line imprint marks, one at the 
AS promoter and the other at exon A/B. Ablation of the non-methylated, paternal AS promoter causes derepression of NESP55, and ablation 
of the non-methylated, paternal exon A/B leads to derepression of Gs; the latter occurs in tissues where the latter is normally silenced from 
the paternal allele (*). Most familial PHP-Ib cases exhibit isolated loss of GNAS exon A/B imprinting. Deletions identified in those cases 
point to a region within the STX16 locus, probably around exon 4, as comprising a cis-acting long-range regulatory element that is necessary 
for the establishment of the maternal exon A/B imprint. All GNAS maternal imprints are lost in most sporadic and some familial PHP-Ib 
cases. Deletions identified in the latter suggest that the NESP55 DMR, which contains not only exon NESP55 but also exons 3 and 4 of the 
AS transcript, comprises a cis-acting element that controls the imprinting of the entire maternal GNAS allele. Arrows indicate the regulatory 
effects revealed by mutations in PHP-Ib and the study of knockout mouse models. mat, maternal; pat, paternal. 408    Current Genomics, 2007, Vol. 8, No. 6  Murat Bastepe 
 
geted disruption of Gnas exon 1. In addition to early embry-
onic lethality observed upon homozygous inheritance of 
exon 1 disruption, even the heterozygous disruption is asso-
ciated with some pre-weaning mortality regardless of the 
parental origin. While this finding is not observed in families 
with PHP-Ia/PPHP, the overall phenotype of mice heterozy-
gous for maternal disruption of Gnas exon 1 resembles that 
of PHP-Ia remarkably. Mice with maternal disruption of 
exon 1 develop biochemical features consistent with PTH 
resistance [41]. In humans with inactivating Gs mutations it 
is accepted that obesity develops regardless of the parent-of-
origin of the introduced mutation, but recent evidence indi-
cates that patients with PHP-Ia exhibit more prominent obe-
sity than patients with PPHP [144]. Consistent with this re-
cent observation, mice with the maternal Gnas exon 1 dis-
ruption is more obese than the paternal disruption [82]. In 
contrast to these similarities between the mouse models of 
exon 1 ablation and PHP-Ia/PPHP, the serum PTH level 
seems to be moderately elevated in mice with paternal Gnas 
exon 1 ablation, suggesting the presence of PTH-resistance 
[41]. This finding is not observed in mice with paternal abla-
tion of exon 2 and may therefore reflect the preservation of 
Gnas transcripts that use exon 2, such as XLs. Although 
this conclusion is contrary to the evidence that XLs can 
mimic Gs [70, 71, 143], it correlates well with the notion 
that Gs and XLs, which are oppositely imprinted in certain 
tissues, mediate opposing actions [67]. 
PHP-Ib 
  Since a 3-kb deletion removing exons 4-6 of the STX16 
locus has been identified in numerous familial PHP-Ib cases, 
and since this locus, with its exon-intron structure and its 
proximity to the GNAS locus, is similar in mice and humans, 
an attempt at generating a PHP-Ib mouse model has been 
made through targeted deletion of Stx16 exons 4-6 [167]. 
Both heterozygous and homozygous mice with this deletion 
lack gross abnormalities, are fertile, and appear to have a 
normal life span. More important, regardless of the parental 
origin of the deletion, the mutant mice fail to phenocopy the 
epigenetic abnormalities found in patients with familial 
PHP-Ib. In fact, neither any other Gnas methylation defects 
nor any biochemical features that would suggest PTH resis-
tance could be observed in these animals. Thus, the nearly 
exact change in the mouse Stx16 gene is not sufficient to 
disrupt Gnas imprinting and to result in PTH resistance, rul-
ing out a disrupted STX16 mRNA and/or protein as the mo-
lecular cause of familial PHP-Ib. This conclusion, which is 
consistent with the evidence that the STX16 locus is not im-
printed, supports the hypothesis that the deletions in this 
gene disrupt a cis-acting long-range regulatory element re-
quired for the proper imprinting of GNAS exon A/B. It ap-
pears that this putative control element is not located within 
Stx16 exons 4-6 in mice. 
SUMMARY AND CONCLUSION  
 GNAS is a complex locus located on the telomeric end of 
chromosome 20q. At least five distinct promoters reside in 
this locus, leading to biallelically, paternally, and/or mater-
nally expressed transcripts from both the sense and antisense 
strands. Expression from this locus is tightly regulated by 
epigenetic mechanisms and cis-acting regulatory elements, 
including non-coding RNA molecules. GNAS encodes Gs, 
one of the subunits of the heterotrimeric stimulatory G pro-
tein, which is essential for the actions of numerous agonists. 
Several human disorders are caused by heterozygous muta-
tions that affect Gs expression and/or activity, and consis-
tent with the tissue-specific paternal silencing of Gs expres-
sion, these disorders are inherited in a parent-of-origin spe-
cific manner. In contrast to Gs, the roles of most of the 
other  GNAS products remain unknown at the cellular and 
molecular level, even though the biological significance of 
these products are clear from gene knockout studies. De-
pending on their parental origin, mutations that affect the 
Gs transcript also disrupt some of the additional GNAS 
transcripts, such as XLs. It is likely that the disruption of 
these additional gene products or alterations in the balance 
between the expression of Gs and these proteins contributes 
to disease pathogenesis. It will therefore be important to in-
vestigate the factors regulating the expression of each GNAS 
product and to determine their cellular actions. Conse-
quently, we will know more about the biological role of this 
gene locus and improve our understanding of the molecular 
mechanisms underlying the GNAS-related disorders. In addi-
tion, we will likely gain further insights into the functional 
significance of complex genes in the genome. 
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